Harry Dolstra

8.0k citations

123 papers · 5.2k indexed · 2 hit papers · h-index 42

Immunology top 0.5%
Oncology top 1%
Hematology top 0.5%
Molecular Biology top 10%
Genetics top 5%

Co-authors: Nicolaas Schaap Willemijn Hobo Robbert van der Voort Frank Preijers Hanny Fredrix Frans Maas Joop H. Jansen Anniek B. van der Waart
Topics: Immune Cell Function and Interaction (69 papers)CAR-T cell therapy research (52 papers)Immunotherapy and Immune Responses (45 papers)
Cited by: Immunology Hematology Oncology
Journals: Journal of Clinical Investigation Nature Communications The Journal of Experimental Medicine
Partner nations: Netherlands United States Germany

In The Last Decade

Harry Dolstra

122 papers receiving 5.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years

2021 223 citations Jakob Passweg, Helen Baldomero et al. Bone Marrow Transplantation profile →
Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022

2022 159 citations John A. Snowden, Isabel Sánchez‐Ortega et al. Bone Marrow Transplantation profile →

Peers

Countries citing papers authored by Harry Dolstra

Since Specialization

Citations

This map shows the geographic impact of Harry Dolstra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Harry Dolstra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Harry Dolstra more than expected).

Fields of papers citing papers by Harry Dolstra

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Harry Dolstra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Harry Dolstra. The network helps show where Harry Dolstra may publish in the future.

Co-authorship network of co-authors of Harry Dolstra

This figure shows the co-authorship network connecting the top 25 collaborators of Harry Dolstra. A scholar is included among the top collaborators of Harry Dolstra based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Harry Dolstra. Harry Dolstra is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Current challenges in cell and gene therapy: a joint view from the European Committee of the International Society for Cell & Gene Therapy (ISCT) and the European Society for Blood and Marrow Transplantation (EBMT) 2024 ·Cytotherapy ·Fermín Sánchez‐Guijo,Joaquim Vives,(unknown),Christian Chabannon,Selim Corbacioglu,Harry Dolstra,Dominique Farge,Nico Gagelmann,(unknown),Jürgen Kuball,Bénédicte Neven,(unknown),Vanderson Rocha,Isabel Sánchez‐Ortega,John A. Snowden,Jaap Jan Zwaginga,Massimiliano Gnecchi,Anna Sureda	10
2	Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey 2023 ·Bone Marrow Transplantation ·Jakob Passweg,Helen Baldomero,Fabio Ciceri,Selim Corbacioglu,Rafael de la Cámara,Harry Dolstra,Bertram Glaß,Raffaella Greco,Donal P. McLornan,Bénédicte Neven,Régis Peffault de Latour,Zinaida Perić,Annalisa Ruggeri,John A. Snowden,Anna Sureda	35
3	Practice harmonization workshops of EBMT: an expert-based approach to generate practical and contemporary guidelines within the arena of hematopoietic cell transplantation and cellular therapy 2023 ·Bone Marrow Transplantation ·Ibrahim Yakoub‐Agha,Raffaella Greco,Francesco Onida,Rafael de la Cámara,Fabio Ciceri,Selim Corbacioglu,Harry Dolstra,Bertram Glaß,Michelle Kenyon,Donal P. McLornan,Bénédicte Neven,Régis Peffault de Latour,Zinaida Perić,Annalisa Ruggeri,John A. Snowden,Anna Sureda,Isabel Sánchez‐Ortega	10
4	Generation of human ILC3 from allogeneic and autologous CD34+ hematopoietic progenitors toward adoptive transfer 2023 ·Cytotherapy ·(unknown),Ingrid Bulder,Carlijn Kuijk,Marion Kleijer,(unknown),(unknown),Nienke J.E. Haverkate,Harry Dolstra,Bianca Blom,Mette D. Hazenberg,Carlijn Voermans	2
5	Human CD34+-derived complete plasmacytoid and conventional dendritic cell vaccine effectively induces antigen-specific CD8+ T cell and NK cell responses in vitro and in vivo 2023 ·Cellular and Molecular Life Sciences ·(unknown),(unknown),Jolanda Brummelman,(unknown),(unknown),(unknown),Dorette S. van Ingen Schenau,Mirjam H.M. Heemskerk,Marieke Griffioen,Michel G.D. Kester,Nicolaas Schaap,Joop H. Jansen,Anniek B. van der Waart,Harry Dolstra,Willemijn Hobo	2
6	Engineering of CD34+ progenitor-derived natural killer cells with higher-affinity CD16a for enhanced antibody-dependent cellular cytotoxicity 2023 ·Cytotherapy ·(unknown),(unknown),(unknown),Anniek B. van der Waart,Willemijn Hobo,Jianming Wu,Nicole M. A. Blijlevens,Joop H. Jansen,Bruce Walcheck,Nicolaas Schaap,Paul K.J.D. de Jonge,Harry Dolstra	6
7	Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey 2022 ·Bone Marrow Transplantation ·Jakob Passweg,Helen Baldomero,Christian Chabannon,Selim Corbacioglu,Rafael de la Cámara,Harry Dolstra,Bertram Glaß,Raffaella Greco,Mohamad Mohty,Bénédicte Neven,Régis Peffault de Latour,Zinaida Perić,John A. Snowden,Ibrahim Yakoub‐Agha,Anna Sureda,Nicolaus Kröger,(unknown)	41
8	Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022breakdown → 2022 ·Bone Marrow Transplantation ·John A. Snowden,Isabel Sánchez‐Ortega,Selim Corbacioglu,Grzegorz Basak,Christian Chabannon,Rafael de la Cámara,Harry Dolstra,Rafael F. Duarte,Bertram Glaß,Raffaella Greco,Arjan C. Lankester,Mohamad Mohty,Bénédicte Neven,Régis Peffault de Latour,Paolo Pedrazzoli,Zinaida Perić,Ibrahim Yakoub‐Agha,Anna Sureda,Nicolaus Kröger,(unknown)	159
9	Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 yearsbreakdown → 2021 ·Bone Marrow Transplantation ·Jakob Passweg,Helen Baldomero,Christian Chabannon,Grzegorz Basak,Rafael de la Cámara,Selim Corbacioglu,Harry Dolstra,Rafael F. Duarte,Bertram Glaß,Raffaella Greco,Arjan C. Lankester,Mohamad Mohty,Régis Peffault de Latour,John A. Snowden,Ibrahim Yakoub‐Agha,Nicolaus Kröger,(unknown)	223
10	Cytotoxic T cells are able to efficiently eliminate cancer cells by additive cytotoxicity 2021 ·Nature Communications ·Bettina Weigelin,Annemieke Th. den Boer,Esther Wagena,Kelly Broen,Harry Dolstra,Rob J. de Boer,Carl G. Figdor,Johannes Textor,Peter Friedl	146
11	Clinically applicable CD34+-derived blood dendritic cell subsets exhibit key subset-specific features and potently boost anti-tumor T and NK cell responses 2021 ·Cancer Immunology Immunotherapy ·(unknown),(unknown),Soley Thordardottir,(unknown),(unknown),Anniek B. van der Waart,J.H. Frederik Falkenburg,Michel G.D. Kester,Iris de Rink,Mirjam H.M. Heemskerk,Jannie Borst,Nicolaas Schaap,Joop H. Jansen,Yanling Xiao,Harry Dolstra,Willemijn Hobo	16
12	TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer 2020 ·OncoImmunology ·(unknown),Janneke S. Hoogstad‐van Evert,(unknown),(unknown),(unknown),Alan J. Korman,Paul K.J.D. de Jonge,Jeannette Cany,Rob Woestenenk,Nicolaas Schaap,Leon F.A.G. Massuger,Joop H. Jansen,Willemijn Hobo,Harry Dolstra	54
13	Cell composition and expansion strategy can reduce the beneficial effect of AKT-inhibition on functionality of CD8+ T cells 2020 ·Cancer Immunology Immunotherapy ·(unknown),Willemijn Hobo,(unknown),(unknown),Nicolaas Schaap,Joop H. Jansen,Anniek B. van der Waart,Harry Dolstra	3
14	IL-15 superagonist N-803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34+ progenitor-derived NK cells 2020 ·Cancer Immunology Immunotherapy ·(unknown),(unknown),Karolin Guldevall,(unknown),Paul K.J.D. de Jonge,Janneke S. Hoogstad‐van Evert,Anniek B. van der Waart,Jeannette Cany,Jeffrey T. Safrit,(unknown),Esther Wagena,Peter Friedl,Björn Önfelt,Leon F.A.G. Massuger,Nicolaas Schaap,Joop H. Jansen,Willemijn Hobo,Harry Dolstra	33
15	PD-L1 siRNA-mediated silencing in acute myeloid leukemia enhances anti-leukemic T cell reactivity 2020 ·Bone Marrow Transplantation ·(unknown),(unknown),(unknown),Anniek B. van der Waart,Diana Campillo-Davó,(unknown),(unknown),Hanny Fredrix,Rob Woestenenk,Loreto Parga‐Vidal,Joop H. Jansen,Nicolaas Schaap,Eva Lion,Harry Dolstra,Willemijn Hobo	15
16	Comprehensive Phenotyping of T Cells Using Flow Cytometry 2019 ·Cytometry Part A ·(unknown),Willemijn Hobo,Rob Woestenenk,Frank Preijers,Harry Dolstra,Anniek B. van der Waart	137
17	PD-L1 microSPECT/CT Imaging for Longitudinal Monitoring of PD-L1 Expression in Syngeneic and Humanized Mouse Models for Cancer 2018 ·Cancer Immunology Research ·Sandra Heskamp,(unknown),Janneke D.M. Molkenboer‐Kuenen,(unknown),Soley Thordardottir,Jeannette Cany,Daniel Olive,Johan Bussink,Otto C. Boerman,Harry Dolstra,Erik H.J.G. Aarntzen,Willemijn Hobo	30
18	Ex vivo AKT-inhibition facilitates generation of polyfunctional stem cell memory-like CD8⁺ T cells for adoptive immunotherapy 2018 ·OncoImmunology ·(unknown),Willemijn Hobo,Yun Ji,Hanny Fredrix,Valeria De Giorgi,Robert D. Allison,Michel G.D. Kester,J.H. Frederik Falkenburg,Nicolaas Schaap,Joop H. Jansen,Luca Gattinoni,Harry Dolstra,Anniek B. van der Waart	45
19	CLEC12A-Mediated Antigen Uptake and Cross-Presentation by Human Dendritic Cell Subsets Efficiently Boost Tumor-Reactive T Cell Responses 2016 ·The Journal of Immunology ·(unknown),Soley Thordardottir,Hanny Fredrix,(unknown),Rob Woestenenk,Jurjen Tel,Ben Joosten,Alessandra Cambi,Mirjam H.M. Heemskerk,Gerben M. Franssen,Otto C. Boerman,(unknown),Joop H. Jansen,Nicolaas Schaap,Harry Dolstra,Willemijn Hobo	40
20	PD-1/PD-L1 Interactions Contribute to Functional T-Cell Impairment in Patients Who Relapse with Cancer After Allogeneic Stem Cell Transplantation 2011 ·Cancer Research ·Wieger J. Norde,Frans Maas,Willemijn Hobo,Alan J. Korman,Michael Quigley,Michel G.D. Kester,Konnie M. Hebeda,J.H. Frederik Falkenburg,Nicolaas Schaap,Theo M. de Witte,Robbert van der Voort,Harry Dolstra	126

About Harry Dolstra

Harry Dolstra is a scholar working on Immunology, Hematology and Oncology, having authored 123 papers that have together received 5.2k indexed citations. Recurring topics across this work include Immune Cell Function and Interaction (69 papers), CAR-T cell therapy research (52 papers) and Immunotherapy and Immune Responses (45 papers). The work is most often cited by research in Immunology (3.3k citations), Hematology (1.6k citations) and Oncology (2.4k citations). Harry Dolstra has collaborated with scholars based in Netherlands, United States and Germany. Frequent co-authors include Nicolaas Schaap, Willemijn Hobo, Robbert van der Voort, Frank Preijers, Hanny Fredrix, Frans Maas, Joop H. Jansen, Anniek B. van der Waart, Theo M. de Witte and Théo de Witte. Their work appears in journals such as Journal of Clinical Investigation, Nature Communications and The Journal of Experimental Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact